Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON54356
NL-OMON54356
Recruiting
Phase 2

FIGO 2018 stage IB2 (>2cm - <=4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) - CONTESSA/NEOCO

Princess Margaret Cancer Centre0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscervical cancercervical carcinoma10038594

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
cervical cancer
Sponsor
Princess Margaret Cancer Centre
Enrollment
40
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients must have histologically confirmed invasive cervical cancer with
  • •adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring
  • •\>2 cm \- \<\=4 cm
  • •Patients must be \>\=18 years of age, and \< 40 years of age
  • •Patients must be premenopausal and wish to preserve fertility
  • •no prior therapy to treat their cancer lesion, patients with diagnostic cone or
  • •LEEP are allowed but a measurable tumor of \>2 cm \- \<\=4 cm is mandatory
  • •Eastern Cooperative Group (ECOG) performance status \<\= 2
  • •Within 7 days of the proposed start of treatment, patients must have normal
  • •organ and marrow function

Exclusion Criteria

  • •Patients who are receiving any other investigational agents.
  • •Patients with other cancers requiring ongoing treatment.
  • •Patients with known / evidence of brain metastases
  • •Uncontrolled inter\-current illness
  • •Patients who are pregnant or breastfeeding

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
FIGO 2018 stage IB2 (>2 cm - =4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)Cervical cancerTherapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2023-507230-24-00niversity Health Network95
Active, not recruiting
Phase 2
IBCSG 24-02 / BIG 2-02: Suppression of Ovarian Function TrialAdjuvant Breast CancerCancer - Breast
ACTRN12605000416695Breast Cancer Trials3,066
Completed
Not Applicable
Early External Cephalic Version (ECV) 2 trialPregnancies with a foetus in breech presentationPregnancy and Childbirth
ISRCTN56498577McMaster University Medical Centre (Canada)1,460
Active, not recruiting
Phase 1
An early phase clinical trial testing a new antibody (BI-1206) for use with rituximab in patients with slow-growing types of Non-Hodgkin Lymphoma that has not responded to or has returned after previous treatment with rituximabIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-000444-26-PLBioInvent International AB52
Active, not recruiting
Phase 1
An early phase clinical trial testing a new antibody (BI-1206) for use with rituximab in patients with slow-growing types of Non-Hodgkin Lymphoma that has not responded to or has returned after previous treatment with rituximabIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-000444-26-ESBioInvent International AB30